艾瑞昔布致急性肝损伤1例

A case of acute liver injury caused by imrecoxib

张标 ¹李华荣 ¹杨远荣¹

扫码查看

作者信息

1. 荆州市中心医院药学部(湖北荆州 434020)
折叠

摘要

1例接受后人路腰椎椎体间融合术治疗的患者术后应用艾瑞昔布后,肝生化检查异常.给予多烯磷脂酰胆碱注射液联合注射用谷胱甘肽护肝治疗,丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(AKP)等生化指标仍进行性升高,峰值分别为404.7,122.8,255.1 U·L-1.停用艾瑞昔布后,调整护肝治疗为多烯磷脂酰胆碱注射液联合注射用复方甘草酸苷,ALT、AST、AKP逐渐降低,至出院前分别为54.6,21.2,137.2 U·L-1.采用RUCAM量表评分进行关联性评价,艾瑞昔布评分为8分,评价结果为很可能.临床在应用艾瑞昔布时应警惕其肝毒性,监测肝功能,以保障患者用药安全.

Abstract

A patient who underwent posterior lumbar interbody fusion was treated with imrecoxib,the patient's liver biochemical examination was abnormal.Follow taking polyene phosphatidylcholine injection combined with glutathione for liver protection,alanine aminotransferase(ALT),aspartate aminotransferase(AST)and alkaline phosphatase(AKP)still increased progressively,with peaks of 404.7,122.8 and 255.1 U·L-1,respectively.With stopping the use of imrecoxib,and adjusting the liver protection treatment of polyene phosphatidylcholine injection combined with compound glycyrrhizin injection,ALT,AST and AKP decreased gradually before discharge and were 54.6,21.2,137.2 U·L-1,respectively.Associations were evaluated by RUCAM rating scale,with an imrecoxib association score of 8,and it may be causing liver damage of this patient.The hepatotoxicity should be vigilant and the liver function should be monitored in application of imrecoxib to ensure the safety of drug in patients.

关键词

艾瑞昔布/药物性肝损伤/RUCAM量表/药品不良反应

Key words

Imericoxib/Drug-induced liver injury/RUCAM scale/Adverse drug reaction

引用本文复制引用

出版年

2024

药物流行病学杂志

中国药学会武汉医药（集团）股份有限公司

药物流行病学杂志

CSTPCD

影响因子：0.746

ISSN：1005-0698

参考文献量10

段落导航